

FIG. 1








FIG. 2





- Natural Human TNF
- Recombinant Human TNF
- Control


FIG. 3



mn059 .0.0







mn059.0.0




FIG. 8A




FIG. 8B




FIG. 9A




FIG. 9B




FIG. 10A




FIG. 10B




FIG. 11




FIG. 12

 $\mathtt{Gl}\mathtt{y}$ Pro Ile Pro Leu Asp Ser Asn Asn Pro Thr Ser Ala Ala Ile His Ile Arg Lys Asn Leu Val Leu Thr Ile Glu Pro Leu lle Leu Leu His Val Gly Leu Tyr Ala Alà Ala TyxGlu Leu Ile Ser Trp Ala Asn Leu Ala Ile Vál 10 Asp Lys Pro Val Glu Leu Ala His Pro Ser Gly Arg Ser Asn Lys Leu Phe Thr Ala Arg Arg Pro Ser Val TYX130 Asp 110 Glu Asn 70 Pro Lys 50 Val 150 Val 30 Ser Leu CysAla Gln Val Thr GlyG1yPro Trp GlyGly $_{
m Gln}$ Glu Lys Gln Leu Gln Thr G1uGlnTyr Ser Arg Leu Asn Pro Leu G1uGlySer Ser Asp $_{
m Gln}$ $L\gamma_S$ $_{
m Gln}$ Thr Ala Val Ser Arg Glu G1yAla Phe Leu Asp Phe Leu Phe Ser Glu Leu IIeArg Val Arg Glu Arg Ala G1y141 Tyr Val 21 Gln 61 Gln Ser GlyCys Val 101 41

FIG. 13






FIG. 14A




FIG. 14B

Lys Pro Val Ala His Val Val Ala Asn Asp Ser Arg Thr.Pro Ser Ser 1 Val Arg Ser (

Pro

Gly

Glu Gly Gln Leu Gln Trp Leu Asn Arg Arg Ala Asn Ala Leu Léu Ala Asn 30 Ala Gln

Ser Pro 50 Val Val Glu Leu Arg Asp Asn Gln Leu Val

Ser Ile Tyr Thr Tyr Leu Ile His Val Leu Leu Thr His Glu Gly Leu Thr Ser Pro CysGlyGln GlyLys Phe Val Leu 61 G1n

Pro Ser Lys Ile Ala 90 Lys Val Asn Leu Leu Ser Gln Thr TYL Ser Val Ala Ile Arg Ser

Leu TYTLle Glu Pro $\mathrm{T}\mathrm{Y}\mathrm{r}$ Trp110 Glu Ala Lys Pro Ala GLYPro Glu Thr Glu Arg. Gln Cys 101

Asp Pro. Ile Asn Arg Glu Ala Leu Ser Arg Asp 130 Phe Gln Leu Glu Lys Gly Val G1y

121

Ile Ala Leu Tyr Phe Gly 1le 150 Val Gln G1ySer Glu Ala Phe .141 Tyr Leu Asp 1

FIG. 15

All. with will find the first first the The Area Are House Land When the

AspileLeuLeuThrGlnSerProAlaIleLeuSerValSerProGlyGluArgValSer GACATCTTGCTGACTCAGTCTCCAGCCATCCTGTCTGTGAGTCCAGGAGAAAGAGTCAGT

TTCTCCTGCAGGGCCAGTCAGTTCGTTGGCTCAAGCATCCACTGGTATCAGCAAAGAACA phesercysArgAlaSerGlnPheValGlySerSerIleHisTrpTyrGlnGlnArgThr AATGGTTCTCCAAGGCTTCTCATAAAGTATGCTTCTGAGTCTATGTCTGGGATCCCTTCC AsnGlySerProArgLeuLeuIleLysTyrAlaSerGluSerMetSerGlyIleProSer

ArgPheSerGlySerGlyThrAspPheThrLeuSerIleAsnThrValGluSer AGGTTTAGTGGCAGTGGATCAGGGACAGATTTTACTCTTAGCATCAACACTGTGGAGTCT

GAAGATATTGCAGATTATTACTGTCAAGAAAGTCATAGCTGGCCATTCACGTTCGGCTCG GluAspIleAlaAspTyrTyrCysGlnGlnSerHisSerTrpProPheThrPheGlySer

GGGACAAATTTGGAAGTAAAA GlyThrAsnLeuGluValLys 16A

The day of the trail has any GAAGTGAAGCTTGAGGAGTCTGGAGGAGGCTTGGTGCAACCTGGAGGATCCATGAAACTC GluvalLysLeuGluGluSerGlyGlyGlyLeuvalGlnProGlyGlySerMetLysLeu

 ${\tt SerCysValAlaSerGlyPheIlePheSerAsnHisTrpMetAsnTrpValArgGlnSer}$ TCCTGTGTGCCTCTGGATTCATTTTCAGTAACCACTGGATGAACTGGGTCCGCCAGTCT


CCAGAGAAGGGGCTTGAGTGGGTTGCTGAAATTAGATCAAAATCTATTAATTCTGCAACA ProGluLysGlyLeuGluTrpValAlaGluIleArgSerLysSerIleAsnSerAlaThr


CATTATGCGGAGTCTGTGAAAGGGAGGTTCACCATCTCAAGAGATGATTCCAAAAGTGCT HisTyrAlaGluSerValLysGlyArgPheThrIleSerArgAspAspSerLysSerAla


GTGTACCTGCAAATGACCGACTTAAGAACTGAAGACACTGGCGTTTTATTACTGTTCCAGG ValTyrLeuGlnMetThrAspLeuArgThrGluAspThrGlyValTyrTyrCysSerArg


AATTACTACGGTAGTACCTACGACTACTGGGGCCAAGGCACCACTCTCACAGTGTCC AsnTyrTyrGlySerThrTyrAspTyrTrpGlyGlnGlyThrThrLeuThrValSer


Docket No.: 0975.1005-014 Title: METHODS OF TREATING MYELODYSPLASTIC .. Inventors: Junming Le, *et al.*





















FIG. 23



Title: METHODS OF TREATING MYELODYSPLASTIC .. Inventors: Junming Le, *et al*.












The thirty from the three the










FIG. 30

the first first out time than the first time than the first time that the first out.




FIG. 31A




FIG. 31B




FIG. 31C




FIG. 32






FIG. 33A









FIG. 33B

















* $p \le 0.05$, ** $p \le 0.01$, *** $p \le 0.001$ versus pre-infusion $p \le 0.05$, $p \le 0.01$, $p \le 0.001$ versus change in placebo group

FIG. 34